Sedana Medical

Sedana Medical's mission is to make inhaled sedation a standard therapy in intensive care, representing a significant shift from decades of IV sedation dominance. The company has achieved commercial traction in Europe with its integrated device-pharma platform, reporting 179 MSEK in 2024 sales, and is actively pursuing U.S. market entry through an Early Access Program. Its strategy focuses on direct sales in key European markets, expanding global distribution, and generating clinical evidence to drive adoption and achieve profitability in its ex-U.S. operations.

The Sedaconda platform combines the Sedaconda ACD (Anaesthetic Conserving Device), a medical device that captures and recirculates exhaled anesthetic, with the pharmaceutical Sedaconda (isoflurane) to enable efficient, long-term inhaled sedation for mechanically ventilated ICU patients.

Competes primarily against generic intravenous sedatives (propofol, benzodiazepines). Faces minimal direct competition from other integrated inhaled sedation platforms currently, but may encounter future entrants. Must overcome deep-seated clinical habits and demonstrate clear economic and clinical superiority.